Measles second dose vaccination coverage and associated factors in Ethiopia: A systematic review and meta-analysis

IF 2.7 Q3 IMMUNOLOGY
Aklilu Alemayehu , Sisay Tefera
{"title":"Measles second dose vaccination coverage and associated factors in Ethiopia: A systematic review and meta-analysis","authors":"Aklilu Alemayehu ,&nbsp;Sisay Tefera","doi":"10.1016/j.jvacx.2025.100675","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><div>Measles-containing vaccine second dose (MCV2) is an important intervention employed to eliminate measles that mainly affect children. Although there are few original studies, comprehensive data that can guide evidence-based decision making to mitigate measles in Ethiopia is limited. Thus, this systematic review and meta-analysis aimed to synthesize evidence to fill this gap.</div></div><div><h3>Methods</h3><div>Online searching, selection, data extraction, and quality assessment were conducted by two authors. Data were extracted using Microsoft Excel Spreadsheet Version 19.0 and analyzed using STATA Version 17.0. Pooled estimates were determined by a random-effect meta-analysis. Sub-group analysis was conducted to account for sources of heterogeneity. Results are presented in narration, tables, and figures.</div></div><div><h3>Results</h3><div>Eight cross-sectional studies involving 4416 participants from four regions of Ethiopia were included in this SRMA. The pooled coverage of MCV2 vaccination in Ethiopia was 50.5 % [95 % confidence interval (CI): 39.0–61.9]. Maternal education [odds ratio (OR) = 2.14 95 % CI: 1.22–3.05)], child delivery in a health facility (OR = 2.16 95 % CI: 1.30–3.02), having knowledge about child immunization (OR = 2.24 95 % CI: 1.61–2.87), favorable attitude towards child immunization (OR = 4.30 95 % CI: 2.63–5.97), having awareness about MCV2 vaccination (OR = 2.04 95 % CI: 1.48–2.59), having postnatal follow-up (OR = 2.52 95 % CI: 1.39–3.65), and utilization of other vaccines and supplements (OR = 4.17 95 % CI: 2.05–6.28) were factors associated with MCV2 vaccination coverage.</div></div><div><h3>Conclusion</h3><div>The coverage of MCV2 vaccination in Ethiopia is sub-optimal. The identified factors should be targeted to improve MCV2 vaccination coverage, and hence strengthen measles mitigation.</div></div>","PeriodicalId":43021,"journal":{"name":"Vaccine: X","volume":"25 ","pages":"Article 100675"},"PeriodicalIF":2.7000,"publicationDate":"2025-06-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Vaccine: X","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2590136225000695","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"IMMUNOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Background

Measles-containing vaccine second dose (MCV2) is an important intervention employed to eliminate measles that mainly affect children. Although there are few original studies, comprehensive data that can guide evidence-based decision making to mitigate measles in Ethiopia is limited. Thus, this systematic review and meta-analysis aimed to synthesize evidence to fill this gap.

Methods

Online searching, selection, data extraction, and quality assessment were conducted by two authors. Data were extracted using Microsoft Excel Spreadsheet Version 19.0 and analyzed using STATA Version 17.0. Pooled estimates were determined by a random-effect meta-analysis. Sub-group analysis was conducted to account for sources of heterogeneity. Results are presented in narration, tables, and figures.

Results

Eight cross-sectional studies involving 4416 participants from four regions of Ethiopia were included in this SRMA. The pooled coverage of MCV2 vaccination in Ethiopia was 50.5 % [95 % confidence interval (CI): 39.0–61.9]. Maternal education [odds ratio (OR) = 2.14 95 % CI: 1.22–3.05)], child delivery in a health facility (OR = 2.16 95 % CI: 1.30–3.02), having knowledge about child immunization (OR = 2.24 95 % CI: 1.61–2.87), favorable attitude towards child immunization (OR = 4.30 95 % CI: 2.63–5.97), having awareness about MCV2 vaccination (OR = 2.04 95 % CI: 1.48–2.59), having postnatal follow-up (OR = 2.52 95 % CI: 1.39–3.65), and utilization of other vaccines and supplements (OR = 4.17 95 % CI: 2.05–6.28) were factors associated with MCV2 vaccination coverage.

Conclusion

The coverage of MCV2 vaccination in Ethiopia is sub-optimal. The identified factors should be targeted to improve MCV2 vaccination coverage, and hence strengthen measles mitigation.
埃塞俄比亚麻疹第二剂疫苗接种覆盖率及相关因素:系统回顾和荟萃分析
背景含麻疹疫苗第二剂(MCV2)是消除主要影响儿童的麻疹的重要干预措施。尽管原始研究很少,但能够指导以证据为基础的决策以减轻埃塞俄比亚麻疹的综合数据有限。因此,本系统综述和荟萃分析旨在综合证据来填补这一空白。方法由两位作者进行在线检索、筛选、资料提取和质量评价。使用Microsoft Excel Version 19.0进行数据提取,使用STATA Version 17.0进行数据分析。汇总估计由随机效应荟萃分析确定。进行亚组分析以解释异质性的来源。结果以叙述、表格和图表的形式呈现。结果8项横断面研究纳入了来自埃塞俄比亚4个地区的4416名参与者。埃塞俄比亚MCV2疫苗接种的总覆盖率为50.5%[95%置信区间(CI): 39.0-61.9]。产妇教育(优势比(或)= 2.14 95%置信区间:1.22 - -3.05)],孩子在卫生设施交付(或= 2.16 95%置信区间:1.30—-3.02),有知识孩子免疫(或= 2.24 95%置信区间:1.61—-2.87),良好的态度儿童免疫接种(OR = 4.30 95%可信区间:2.63 - -5.97),在对MCV2接种疫苗(或= 2.04 95%置信区间:1.48—-2.59),在产后随访(或= 2.52 95%置信区间:1.39—-3.65),利用其他疫苗和补充剂(OR = 4.17 95% CI:2.05-6.28)是与MCV2疫苗接种覆盖率相关的因素。结论埃塞俄比亚MCV2疫苗接种覆盖率不理想。应以确定的因素为目标,提高MCV2疫苗接种覆盖率,从而加强麻疹缓解。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Vaccine: X
Vaccine: X Multiple-
CiteScore
2.80
自引率
2.60%
发文量
102
审稿时长
13 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信